Physician profile
Kevin R Mathisson
NPI 1326076639
$4,907.61
in general payments reported to CMS, 2019-2025
21 companies · $1,372 in 2025
The $1,372 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $129 · 2021: $435 · 2022: $933 · 2023: $686 · 2024: $890 · 2025: $1,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,946.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,054.31 | 2022-2025 | |
| Alcon Vision LLC | $839.33 | 2019-2025 | Clareon, Clareon Panoptix Pro, Unity |
| Bausch & Lomb Americas INC. | $586.17 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $530.40 | 2019-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $317.94 | 2019-2021 | |
| Allergan, INC. | $262.24 | 2019-2022 | |
| New World Medical,INC. | $250.00 | 2022 | |
| Oyster Point Pharma, INC. | $247.36 | 2022-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $170.37 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $133.53 | 2024-2025 | Vevye |
| Eyepoint US, INC. | $125.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $118.05 | 2019-2023 | |
| Shire North American Group INC | $64.51 | 2019 | |
| Rxsight INC | $47.92 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Johnson & Johnson Surgical Vision, INC. | $29.22 | 2023 | Tecnis Simplicity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $25.00 | 2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $24.41 | 2021 | |
| Kala Pharmaceuticals, INC. | $23.57 | 2022 | |
| Thea Pharma INC. | $21.10 | 2023 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Ocular Therapeutix, INC. | $17.78 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Mathisson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.